TFF Pharmaceuticals, Inc.

Pharmaceutical Preparations·AUSTIN, TX

CEO

Weisman Harlan F

CFO

Coleman Kirk Allen

Financials

20 shown

Type	Period	Ended	Filed
10-Q	Q3 2024	9/30/24	11/20/24	→
10-Q	Q2 2024	6/30/24	8/14/24	→
10-Q	Q1 2024	3/31/24	5/14/24	→
10-K	FY 2023	12/31/23	3/28/24	→
10-Q	Q3 2023	9/30/23	11/14/23	→
10-Q	Q2 2023	6/30/23	8/14/23	→
↓

Earnings Releases (8-K)

19 shown

Filed	Period
8/14/24	Q3 FY2024	→
5/14/24	Q2 FY2024	→
3/28/24	Q1 FY2024	→
11/14/23	Q4 FY2023	→
8/15/23	Q3 FY2023	→
5/11/23	Q2 FY2023	→
↓

News (8-K)

41 shown

Filed	Type	Description
3/6/25	Vote	Submission of Matters to a Vote of Security Holders	→
2/3/25	Vote	Unregistered Sales of Equity Securities	→
12/10/24	Delisting	Notice of Delisting or Failure to Satisfy a Continued Listing Rule	→
11/14/24	Exec Change	Termination of a Material Definitive Agreement	→
8/6/24	Reg FD	Regulation FD Disclosure	→
7/1/24	Exec Change	Departure or Appointment of Directors or Certain Officers	→
↓

Prospectuses & Registrations

37 shown

Filed	Form	Description
3/6/25	S-8 POS	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8	→
3/6/25	S-8 POS	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8	→
3/6/25	S-8 POS	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8	→
6/14/24	S-8	REGISTRATION STATEMENT	→
5/17/24	424B5	PROSPECTUS SUPPLEMENT	→
5/1/24	424B4	424B4	→
↓

Filing History(317 filings)

TypeDateAccessionPeriodSize

EFFECT

Mar 7, 2025

9999999995-25-000602

—

1.7 KB

EFFECT

Mar 7, 2025

9999999995-25-000601

—

1.7 KB

EFFECT

Mar 7, 2025

9999999995-25-000600

—

1.7 KB

EFFECT

Mar 7, 2025

9999999995-25-000599

—

1.7 KB

Mar 6, 2025

0001213900-25-021257FORM 25

—

13.5 KB

S-8 POS

Mar 6, 2025

0001213900-25-021245POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

—

23.5 KB

S-8 POS

Mar 6, 2025

0001213900-25-021242POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

—

23.5 KB

S-8 POS

Mar 6, 2025

0001213900-25-021236POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

—

23.5 KB

POS AM

Mar 6, 2025

0001213900-25-021117POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

—

26.3 KB

POS AM

Mar 6, 2025

0001213900-25-021116POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

—

26.3 KB

POS AM

Mar 6, 2025

0001213900-25-021115POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1

—

26.3 KB

POS AM

Mar 6, 2025

0001213900-25-021109POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3

—

22.5 KB

8-K

Mar 6, 2025

0001213900-25-021099CURRENT REPORT

Mar 3, 2025

200.0 KB

DEFA14A

Feb 4, 2025

0001213900-25-010073DEFINITIVE ADDITIONAL MATERIALS

—

27.7 KB

8-K

Feb 3, 2025

0001213900-25-009477CURRENT REPORT

Jan 28, 2025

206.4 KB

DEF 14A

Dec 23, 2024

0001213900-24-111481PROXY STATEMENT

Jan 28, 2025

475.3 KB

PRE 14A

Dec 11, 2024

0001213900-24-107883PROXY STATEMENT

Dec 11, 2024

476.6 KB

8-K

Dec 10, 2024

0001213900-24-107409CURRENT REPORT

Dec 4, 2024

196.2 KB

10-Q

Nov 20, 2024

0001213900-24-100587QUARTERLY REPORT

Sep 30, 2024

4.1 MB

SC 13G/A

Nov 19, 2024

0001193125-24-261722SC 13G/A

—

79.7 KB

NT 10-Q

Nov 14, 2024

0001213900-24-098467NOTIFICATION OF LATE FILING

Sep 30, 2024

44.6 KB

8-K

Nov 14, 2024

0001213900-24-098457CURRENT REPORT

Nov 14, 2024

215.1 KB

SC 13G

Nov 14, 2024

0001172661-24-005108

—

88.3 KB

8-K

Aug 14, 2024

0001213900-24-068991CURRENT REPORT

Aug 14, 2024

285.3 KB

10-Q

Aug 14, 2024

0001213900-24-068964QUARTERLY REPORT

Jun 30, 2024

4.2 MB

25 filings shown

TFF Pharmaceuticals, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(317 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/4/25	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
12/23/24	DEF 14A	DEF 14A	→
12/11/24	PRE 14A	PRE 14A	→
4/22/24	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
4/22/24	DEF 14A	DEF 14A	→
10/4/23	DEF 14A	DEF 14A	→
↓

Filed	Form	Description
11/19/24	SC 13G/A	SC 13G/A	→
11/14/24	SC 13G	SC 13G	→
7/8/24	4	4	→
7/8/24	4	4	→
7/8/24	4	4	→
7/8/24	4	4	→
↓

Filed	Form	Description
3/7/25	EFFECT	EFFECT	→
3/7/25	EFFECT	EFFECT	→
3/7/25	EFFECT	EFFECT	→
3/7/25	EFFECT	EFFECT	→
3/6/25	25	FORM 25	→
3/6/25	POS AM	POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1	→
↓